Effect of ivermectin in COVID-19

Phase 2

Recruiting

• Conditions: Condition 1: COVID-19. Condition 2: COVID-19.; virus identified; virus not identified; Clinically-epidemiologically diagnosed COVID-19; Probable COVID-19; Suspected COVID-19; U07.1; U07.2

• Registration Number: IRCT20200329046892N3
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

All Covid-19 patients admitted to the coronavirus ward of Razi Hospital in Rasht for period of April to July 2021
Age greater than or equal to 18 years
Patients admitted with the following criteria: fever (oral temperature greater than 37.2 ° C), dry cough, severe tiredness or dyspnea
At least one of the following criteria : positive PCR OR lung involvement on chest X-ray / CT scan

Exclusion Criteria

Lack of informed consent
Lack of patient cooperation
Having pulmonary embolism or intravascular thrombosis
Any major drug interaction between routine patient's drugs with any of the study drugs
Pregnancy and lactation
Simultaneous presence in other research study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The time required to improve clinical symptoms within 10 days of treatment start. Timepoint: Daily from the first day of intervention. Method of measurement: Physical examination.